GW Pharmaceuticals Market Cap 2013-2019 | GWPH
GW Pharmaceuticals market cap history and chart from 2013 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. GW Pharmaceuticals market cap as of July 16, 2019 is $5.06B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $5.057B | $0.013B |
| GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $147.856B | 28.70 |
| Medtronic (MDT) | Ireland | $133.874B | 19.12 |
| Stryker (SYK) | United States | $76.669B | 27.36 |
| Boston Scientific (BSX) | United States | $59.033B | 28.30 |
| Baxter (BAX) | United States | $41.839B | 26.37 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $29.060B | 0.00 |
| Coloplast (CLPBY) | Denmark | $25.618B | 40.90 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.965B | 16.04 |
| Lonza Group Ag (LZAGY) | Switzerland | $24.947B | 0.00 |
| Terumo (TRUMY) | Japan | $23.393B | 26.90 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $19.274B | 0.00 |
| ResMed (RMD) | United States | $17.745B | 33.90 |
| Canopy Growth (CGC) | Canada | $12.161B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $12.027B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.308B | 49.34 |
| William Demant Holdings (WILYY) | Denmark | $7.651B | 0.00 |
| Insulet (PODD) | United States | $7.203B | 524.78 |
| Aurora Cannabis (ACB) | Canada | $7.109B | 70.10 |
| Perrigo (PRGO) | Ireland | $7.004B | 11.84 |
| Hill-Rom Holdings (HRC) | United States | $6.993B | 21.20 |
| GN STORE NORD (GNNDY) | Denmark | $6.409B | 32.73 |
| Haemonetics (HAE) | United States | $6.325B | 51.63 |
| ICU Medical (ICUI) | United States | $5.135B | 30.64 |
| Neogen (NEOG) | United States | $3.349B | 54.45 |
| NuVasive (NUVA) | United States | $2.982B | 24.36 |
| Hutchison China MediTech (HCM) | China | $2.925B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.711B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.420B | 51.57 |
| Quidel (QDEL) | United States | $2.309B | 23.96 |
| Cardiovascular Systems (CSII) | United States | $1.598B | 917.80 |
| Aphria (APHA) | $1.579B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.229B | 18.41 |
| AtriCure (ATRC) | United States | $1.218B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.187B | 25.19 |
| Lantheus Holdings (LNTH) | United States | $1.089B | 28.93 |
| NanoString Technologies (NSTG) | United States | $1.056B | 0.00 |
| PetIQ (PETQ) | United States | $0.994B | 24.14 |
| MacroGenics (MGNX) | United States | $0.777B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.765B | 21.47 |
| Cerus (CERS) | United States | $0.758B | 0.00 |
| Quanterix (QTRX) | United States | $0.753B | 0.00 |
| Omeros (OMER) | United States | $0.750B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.698B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.572B | 27.71 |
| Surmodics (SRDX) | United States | $0.543B | 78.88 |
| OraSure Technologies (OSUR) | United States | $0.531B | 24.43 |
| Meridian Bioscience (VIVO) | United States | $0.476B | 14.56 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.404B | 0.00 |
| Vapotherm (VAPO) | United States | $0.345B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.320B | 22.13 |
| BioLife Solutions (BLFS) | United States | $0.304B | 95.24 |
| Zynex (ZYXI) | United States | $0.250B | 25.67 |
| Bovie Medical (APYX) | United States | $0.236B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.227B | 0.00 |
| Owens & Minor (OMI) | United States | $0.198B | 4.20 |
| Chimerix (CMRX) | United States | $0.188B | 0.00 |
| United Health Products (UEEC) | United States | $0.175B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.170B | 0.00 |
| Female Health (VERU) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.139B | 7.33 |
| Chembio Diagnostics (CEMI) | United States | $0.098B | 0.00 |
| United-Guardian (UG) | United States | $0.094B | 20.65 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Surface Oncology (SURF) | United States | $0.075B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.060B | 20.75 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.058B | 0.00 |
| MRI INTERVENTNS (MRIC) | United States | $0.052B | 0.00 |
